Renal & Urology News -- Studies of anemia management in CKD patients have shown an increased risk of death and cardiovascular morbidity associated with high hemoglobin targets, but new data suggest that the presence of comorbidities such as heart failure or diabetes renders these risks clinically undetectable.
